Pharmacotherapeutics of SARS-CoV-2 Infections

Bhavesh D. Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M. Senan, Santhi Gorantla, Jo Ellyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B. Gurumurthy, St Patrick M. Reid, Chamindie Punyadeera, Linda Chang, Howard E. Gendelman

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.]

Original languageEnglish (US)
Pages (from-to)12-37
Number of pages26
JournalJournal of Neuroimmune Pharmacology
Issue number1
StatePublished - Mar 2021


  • Antibodies
  • Antivirals
  • COVID-19 therapeutics
  • SARS-CoV-2
  • Vaccine

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Pharmacotherapeutics of SARS-CoV-2 Infections'. Together they form a unique fingerprint.

Cite this